Immuno-oncology Assay Market by Product (Consumables and Software), by Technology (Immunoassays, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Flow Cytometry), Application (Research & Development and Clinical Diagnostics), and Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
The global immuno-oncology assay market accounted for $2,769.50 million in 2018, and is expected to reach $ 6,179.20 million by 2026, growing at a CAGR of 10.6% from 2019 to 2026. Immuno-oncology assays are widely being used for the diagnosis of different types of cancer. In addition, this assay provides a gain in assay dynamic range,and is used to amplify multiple targets in a polymerase chain reaction (PCR) and collect more information from minute quantities of proteins or other analytes in lesser time. Immuno-oncology assays find its application in pathogen identification, mutation analysis, RNA detection, gene detection analysis, linkage analysis, and others.
The global immuno-oncology assay market is witnessing significant growth, owing to increase in R&D activities in pharmaceuticals for the treatment of cancer. These assays are used in clinical trials, as they decrease the cost of research & manual labor and increase the efficiency of experiments and therapies. Moreover, they allow to understand a compound’s response precisely intended to mimic the tumor microenvironment. Optimized cell-based assays deliver crucial information to confirm the efficiency of a drug or a compound in simple and progressively complex co-culture assays. In addition, they offer easier & faster analysis of cancer, and are automated as compared to conventional methods, thus fueling the market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. On the contrary, technological development of automated immuno-oncology assay is anticipated to create lucrative opportunities for market expansion in the near future.
The global immuno-oncology assay market is segmented into product, technology, indication, application, and region. On the basis of product, the market is bifurcated into consumables and software. By technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. As per indication, it is divided into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. The applications covered in the study include clinical diagnostics and research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Product
The global immuno-oncology assay market is witnessing significant growth, owing to increase in R&D activities in pharmaceuticals for the treatment of cancer. These assays are used in clinical trials, as they decrease the cost of research & manual labor and increase the efficiency of experiments and therapies. Moreover, they allow to understand a compound’s response precisely intended to mimic the tumor microenvironment. Optimized cell-based assays deliver crucial information to confirm the efficiency of a drug or a compound in simple and progressively complex co-culture assays. In addition, they offer easier & faster analysis of cancer, and are automated as compared to conventional methods, thus fueling the market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. On the contrary, technological development of automated immuno-oncology assay is anticipated to create lucrative opportunities for market expansion in the near future.
The global immuno-oncology assay market is segmented into product, technology, indication, application, and region. On the basis of product, the market is bifurcated into consumables and software. By technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. As per indication, it is divided into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. The applications covered in the study include clinical diagnostics and research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global immune-oncology assaymarketalong with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided.
- A comprehensive quantitative analysis of the industry is provided from 2018 to 2025to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the global trendsin the immune-oncology assaymarket.
- Key players andtheir strategies areprovided to understand the competitive outlook of theindustry.
By Product
- Consumables
- Software
- Immunoassay
- PCR
- NGS
- Flow Cytometry
- Others
- Colorectal Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Others
- Clinical Diagnostics
- Research
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Saudi Arabia
- South Africa
- Brazil
- Rest of LAMEA
- Luminex Corporation
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Becton, Dickinson and Company
- Abcam PLC
- Seegene Inc.
- Randox Laboratories Ltd.
- Merck KGaA
- Agilent Technologies
- Quanterix
- Olink
- Sysmex Corporation
- Siemens Healthcare GmbH
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.4. Porter’s five forces analysis
3.4.1. Moderate bargaining power of buyers
3.4.2. Low bargaining power of suppliers
3.4.3. Moderate threat of substitutes
3.4.4. Low threat of new entrants
3.4.5. Moderate competitive rivalry
3.5. Market share analysis, 2018
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in biotechnology R&D activities & governmental funding
3.6.1.2. Surge in adoption of multiplex immuno-oncology assay to reduce operation costs
3.6.1.3. Rise in adoption of personalized medicines
3.6.2. Restraint
3.6.2.1. Dearth of skilled labor/healthcare professionals
3.6.3. Opportunity
3.6.3.1. Various growth opportunities in emerging economies
CHAPTER 4: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Software
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
CHAPTER 5: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunoassays
5.2.2. Market size and forecast
5.2.3. Market share analysis, by country
5.3. Polymerase chain reaction (PCR)
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Next-generation sequencing (NGS)
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Flow cytometry
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
CHAPTER 6: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Colorectal cancer
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Lung Cancer
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.5. Melanoma cancer
6.5.1. Market size and forecast
6.5.2. Market share analysis, by country
6.7. Bladder Cancer
6.7.1. Market size and forecast
6.7.2. Market share analysis, by country
6.9. Others
6.9.1. Market size and forecast
6.9.2. Market share analysis, by country
CHAPTER 7: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Research & development
7.2.1. Market size and forecast
7.2.2. Market share analysis, by country
7.3. Clinical diagnostics
7.3.1. Market size and forecast
7.3.2. Market share analysis, by country
CHAPTER 8: IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. Market size and forecast, by country
8.2.3. North America market size and forecast, by product
8.2.4. North America market size and forecast, by technology
8.2.5. North America market size and forecast, by indication
8.2.6. North America market size and forecast, by application
8.2.6.1. U.S. market size and forecast, by product
8.2.6.2. U.S. market size and forecast, by technology
8.2.6.3. U.S. market size and forecast, by indication
8.2.6.4. U.S. market size and forecast, by application
8.2.6.5. Canada market size and forecast, by product
8.2.6.6. Canada market size and forecast, by technology
8.2.6.7. Canada market size and forecast, by indication
8.2.6.8. Canada market size and forecast, by application
8.2.6.9. Mexico market size and forecast, by product
8.2.6.10. Mexico market size and forecast, by technology
8.2.6.11. Mexico market size and forecast, by indication
8.2.6.12. Mexico market size and forecast, by application
8.3. Europe
8.3.1. Key growth factors and opportunities
8.3.2. Market size and forecast, by country
8.3.3. Europe market size and forecast, by product
8.3.4. Europe market size and forecast, by technology
8.3.5. Europe market size and forecast, by indication
8.3.6. Europe market size and forecast, by application
8.3.6.1. Germany market size and forecast, by product
8.3.6.2. Germany market size and forecast, by technology
8.3.6.3. Germany market size and forecast, by indication
8.3.6.4. Germany market size and forecast, by application
8.3.6.5. France market size and forecast, by product
8.3.6.6. France market size and forecast, by technology
8.3.6.7. France market size and forecast, by indication
8.3.6.8. France market size and forecast, by application
8.3.6.9. UK market size and forecast, by product
8.3.6.10. UK market size and forecast, by technology
8.3.6.11. UK market size and forecast, by indication
8.3.6.12. UK market size and forecast, by application
8.3.6.13. Italy market size and forecast, by product
8.3.6.14. Italy market size and forecast, by technology
8.3.6.15. Italy market size and forecast, by indication
8.3.6.16. Italy market size and forecast, by application
8.3.6.17. Rest of Europe market size and forecast, by product
8.3.6.18. Rest of Europe market size and forecast, by technology
8.3.6.19. Rest of Europe market size and forecast, by indication
8.3.6.20. Rest of Europe market size and forecast, by application
8.4. Asia-Pacific
8.4.1. Key growth factors and opportunities.
8.4.2. Asia-Pacific market size and forecast, by country
8.4.3. Asia-Pacific market size and forecast, by product
8.4.4. Asia-Pacific market size and forecast, by technology
8.4.5. Asia-Pacific market size and forecast, by indication
8.4.6. Asia-Pacific market size and forecast, by application
8.4.6.1. Japan market size and forecast, by product
8.4.6.2. Japan market size and forecast, by technology
8.4.6.3. Japan Market size and forecast, by indication
8.4.6.4. Japan market size and forecast, by application
8.4.6.5. China market size and forecast, by product
8.4.6.6. China market size and forecast, by technology
8.4.6.7. China market size and forecast, by indication
8.4.6.8. China market size and forecast, by application
8.4.6.9. India market size and forecast, by product
8.4.6.10. India market size and forecast, by technology
8.4.6.11. India market size and forecast, by indication
8.4.6.12. India market size and forecast, by application
8.4.6.13. Rest of Asia-Pacific market size and forecast, by product
8.4.6.14. Rest of Asia-Pacific market size and forecast, by technology
8.4.6.15. Rest of Asia-Pacific market size and forecast, by indication
8.4.6.16. Rest of Asia-Pacific market size and forecast, by application
8.5. LAMEA
8.5.1. Key growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country
8.5.3. LAMEA market size and forecast, by product
8.5.4. LAMEA market size and forecast, by technology
8.5.5. LAMEA market size and forecast, by indication
8.5.6. LAMEA market size and forecast, by application
8.5.6.1. Brazil market size and forecast, by product
8.5.6.2. Brazil market size and forecast, by technology
8.5.6.3. Market size and forecast, by indication
8.5.6.4. Brazil market size and forecast, by application
8.5.6.5. Saudi Arabia market size and forecast, by product
8.5.6.6. Saudi Arabia market size and forecast, by technology
8.5.6.7. Market size and forecast, by indication
8.5.6.8. Saudi Arabia market size and forecast, by application
8.5.6.9. South Africa market size and forecast, by product
8.5.6.10. South Africa market size and forecast, by technology
8.5.6.11. South Africa market size and forecast, by indication
8.5.6.12. South Africa market size and forecast, by application
8.5.6.13. Rest of LAMEA market size and forecast, by product
8.5.6.14. Rest of LAMEA market size and forecast, by technology
8.5.6.15. Rest of LAMEA market size and forecast, by indication
8.5.6.16. Rest of LAMEA market size and forecast, by application
CHAPTER 9: COMPANY PROFILES
9.1. AGILENT TECHNOLOGIES, INC.
9.1.1. Company overview
9.1.1.1. Company snapshot
9.1.2. Operating business segments
9.1.3. Product portfolio
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. BIO-RAD LABORATORIES, INC.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance
9.3. Charles River Laboratories, Inc.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. F. HOFFMANN-LA ROCHE LTD.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. ILLUMINA, INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments
9.6. NanoString Technologies, Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.7. PERKINELMER, INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments
9.8. QIAGEN N.V.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sartorius AG
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. THERMO FISHER SCIENTIFIC, INC.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.4. Porter’s five forces analysis
3.4.1. Moderate bargaining power of buyers
3.4.2. Low bargaining power of suppliers
3.4.3. Moderate threat of substitutes
3.4.4. Low threat of new entrants
3.4.5. Moderate competitive rivalry
3.5. Market share analysis, 2018
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in biotechnology R&D activities & governmental funding
3.6.1.2. Surge in adoption of multiplex immuno-oncology assay to reduce operation costs
3.6.1.3. Rise in adoption of personalized medicines
3.6.2. Restraint
3.6.2.1. Dearth of skilled labor/healthcare professionals
3.6.3. Opportunity
3.6.3.1. Various growth opportunities in emerging economies
CHAPTER 4: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Software
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
CHAPTER 5: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunoassays
5.2.2. Market size and forecast
5.2.3. Market share analysis, by country
5.3. Polymerase chain reaction (PCR)
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Next-generation sequencing (NGS)
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Flow cytometry
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
CHAPTER 6: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Colorectal cancer
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Lung Cancer
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.5. Melanoma cancer
6.5.1. Market size and forecast
6.5.2. Market share analysis, by country
6.7. Bladder Cancer
6.7.1. Market size and forecast
6.7.2. Market share analysis, by country
6.9. Others
6.9.1. Market size and forecast
6.9.2. Market share analysis, by country
CHAPTER 7: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Research & development
7.2.1. Market size and forecast
7.2.2. Market share analysis, by country
7.3. Clinical diagnostics
7.3.1. Market size and forecast
7.3.2. Market share analysis, by country
CHAPTER 8: IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. Market size and forecast, by country
8.2.3. North America market size and forecast, by product
8.2.4. North America market size and forecast, by technology
8.2.5. North America market size and forecast, by indication
8.2.6. North America market size and forecast, by application
8.2.6.1. U.S. market size and forecast, by product
8.2.6.2. U.S. market size and forecast, by technology
8.2.6.3. U.S. market size and forecast, by indication
8.2.6.4. U.S. market size and forecast, by application
8.2.6.5. Canada market size and forecast, by product
8.2.6.6. Canada market size and forecast, by technology
8.2.6.7. Canada market size and forecast, by indication
8.2.6.8. Canada market size and forecast, by application
8.2.6.9. Mexico market size and forecast, by product
8.2.6.10. Mexico market size and forecast, by technology
8.2.6.11. Mexico market size and forecast, by indication
8.2.6.12. Mexico market size and forecast, by application
8.3. Europe
8.3.1. Key growth factors and opportunities
8.3.2. Market size and forecast, by country
8.3.3. Europe market size and forecast, by product
8.3.4. Europe market size and forecast, by technology
8.3.5. Europe market size and forecast, by indication
8.3.6. Europe market size and forecast, by application
8.3.6.1. Germany market size and forecast, by product
8.3.6.2. Germany market size and forecast, by technology
8.3.6.3. Germany market size and forecast, by indication
8.3.6.4. Germany market size and forecast, by application
8.3.6.5. France market size and forecast, by product
8.3.6.6. France market size and forecast, by technology
8.3.6.7. France market size and forecast, by indication
8.3.6.8. France market size and forecast, by application
8.3.6.9. UK market size and forecast, by product
8.3.6.10. UK market size and forecast, by technology
8.3.6.11. UK market size and forecast, by indication
8.3.6.12. UK market size and forecast, by application
8.3.6.13. Italy market size and forecast, by product
8.3.6.14. Italy market size and forecast, by technology
8.3.6.15. Italy market size and forecast, by indication
8.3.6.16. Italy market size and forecast, by application
8.3.6.17. Rest of Europe market size and forecast, by product
8.3.6.18. Rest of Europe market size and forecast, by technology
8.3.6.19. Rest of Europe market size and forecast, by indication
8.3.6.20. Rest of Europe market size and forecast, by application
8.4. Asia-Pacific
8.4.1. Key growth factors and opportunities.
8.4.2. Asia-Pacific market size and forecast, by country
8.4.3. Asia-Pacific market size and forecast, by product
8.4.4. Asia-Pacific market size and forecast, by technology
8.4.5. Asia-Pacific market size and forecast, by indication
8.4.6. Asia-Pacific market size and forecast, by application
8.4.6.1. Japan market size and forecast, by product
8.4.6.2. Japan market size and forecast, by technology
8.4.6.3. Japan Market size and forecast, by indication
8.4.6.4. Japan market size and forecast, by application
8.4.6.5. China market size and forecast, by product
8.4.6.6. China market size and forecast, by technology
8.4.6.7. China market size and forecast, by indication
8.4.6.8. China market size and forecast, by application
8.4.6.9. India market size and forecast, by product
8.4.6.10. India market size and forecast, by technology
8.4.6.11. India market size and forecast, by indication
8.4.6.12. India market size and forecast, by application
8.4.6.13. Rest of Asia-Pacific market size and forecast, by product
8.4.6.14. Rest of Asia-Pacific market size and forecast, by technology
8.4.6.15. Rest of Asia-Pacific market size and forecast, by indication
8.4.6.16. Rest of Asia-Pacific market size and forecast, by application
8.5. LAMEA
8.5.1. Key growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country
8.5.3. LAMEA market size and forecast, by product
8.5.4. LAMEA market size and forecast, by technology
8.5.5. LAMEA market size and forecast, by indication
8.5.6. LAMEA market size and forecast, by application
8.5.6.1. Brazil market size and forecast, by product
8.5.6.2. Brazil market size and forecast, by technology
8.5.6.3. Market size and forecast, by indication
8.5.6.4. Brazil market size and forecast, by application
8.5.6.5. Saudi Arabia market size and forecast, by product
8.5.6.6. Saudi Arabia market size and forecast, by technology
8.5.6.7. Market size and forecast, by indication
8.5.6.8. Saudi Arabia market size and forecast, by application
8.5.6.9. South Africa market size and forecast, by product
8.5.6.10. South Africa market size and forecast, by technology
8.5.6.11. South Africa market size and forecast, by indication
8.5.6.12. South Africa market size and forecast, by application
8.5.6.13. Rest of LAMEA market size and forecast, by product
8.5.6.14. Rest of LAMEA market size and forecast, by technology
8.5.6.15. Rest of LAMEA market size and forecast, by indication
8.5.6.16. Rest of LAMEA market size and forecast, by application
CHAPTER 9: COMPANY PROFILES
9.1. AGILENT TECHNOLOGIES, INC.
9.1.1. Company overview
9.1.1.1. Company snapshot
9.1.2. Operating business segments
9.1.3. Product portfolio
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. BIO-RAD LABORATORIES, INC.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance
9.3. Charles River Laboratories, Inc.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. F. HOFFMANN-LA ROCHE LTD.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments
9.5. ILLUMINA, INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments
9.6. NanoString Technologies, Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.7. PERKINELMER, INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments
9.8. QIAGEN N.V.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sartorius AG
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. THERMO FISHER SCIENTIFIC, INC.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 02. IMMUNO-ONCOLOGY ASSAY MARKET FOR CONSUMBALES, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IMMUNO-ONCOLOGY ASSAY SOFTWARE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 05. IMMUNO-ONCOLOGY ASSAY MARKET, FOR IMMUNOASSAY, BY REGION, 2018–2026 ($MILLION)
TABLE 06. IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY REGION, 2018–2026 ($MILLION)
TABLE 07. IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION)
TABLE 08. IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 10. IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 11. IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 12. IMMUNO-ONCOLOGY MARKET FOR MELANOMA, BY REGION, 2018–2026 ($MILLION)
TABLE 13. IMMUNO-ONCOLOGY MARKET FOR BLADDER CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 14. IMMUNO-ONCOLOGY MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15. IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 16. IMMUNO-ONCOLOGY ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2018–2026 ($MILLION)
TABLE 17. IMMUNO-ONCOLOGY ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2026 ($MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 21. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 22. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY PRODUCT, 2018–2026 ($MILLION)
TABLE 25. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 26. US IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 27. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY APPLICATION, 2018–2026 ($MILLION)
TABLE 28. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 29. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 30. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 31. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 32. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 33. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 34. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 35. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 38. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 39. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 40. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 42. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 43. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 44. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 46. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 47. FRANCE AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 48. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 50. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 51. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 54. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 55. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 56. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 57. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 58. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 59. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 60. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 63. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 64. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 66. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 67. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 68. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 69. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 70. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 71. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 72. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 73. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 74. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 75. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 76. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 77. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 80. REST OF ASIA PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 82. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 83. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 84. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 85. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 86. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 87. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 88. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 89. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 90. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 91. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 92. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 93. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 94. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 95. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 96. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 97. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 98. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 99. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 100. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 101. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 102. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 103. AGILENT: OPERATING SEGMENTS
TABLE 104. AGILENT: PRODUCT PORTFOLIO
TABLE 105. BIO-RAD: COMPANY SNAPSHOT
TABLE 106. BIO-RAD: OPERATING SEGMENTS
TABLE 107. BIO-RAD: PRODUCT PORTFOLIO
TABLE 108. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 109. CHARLES RIVER: OPERATING SEGMENTS
TABLE 110. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 111. ROCHE: COMPANY SNAPSHOT
TABLE 112. ROCHE: OPERATING SEGMENTS
TABLE 113. ROCHE: PRODUCT PORTFOLIO
TABLE 114. ILLUMINA: COMPANY SNAPSHOT
TABLE 115. ILLUMINA: OPERATING SEGMENTS
TABLE 116. ILLUMINA: PRODUCT PORTFOLIO
TABLE 117. NANOSTRING: COMPANY SNAPSHOT
TABLE 118. NANOSTRING: PRODUCT PORTFOLIO
TABLE 119. PERKINELMER: COMPANY SNAPSHOT
TABLE 120. PERKINELMER: OPERATING SEGMENTS
TABLE 121. PERKINELMER: PRODUCT PORTFOLIO
TABLE 122. QIAGEN: COMPANY SNAPSHOT
TABLE 123. QIAGEN: OPERATING SEGMENTS
TABLE 124. QIAGEN: PRODUCT PORTFOLIO
TABLE 125. SARTORIUS: COMPANY SNAPSHOT
TABLE 126. SARTORIUS: OPERATING SEGMENTS
TABLE 127. SARTORIUS: PRODUCT PORTFOLIO
TABLE 128. THERMO FISHER: COMPANY SNAPSHOT
TABLE 129. THERMO FISHER: OPERATING SEGMENTS
TABLE 130. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 02. IMMUNO-ONCOLOGY ASSAY MARKET FOR CONSUMBALES, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IMMUNO-ONCOLOGY ASSAY SOFTWARE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 05. IMMUNO-ONCOLOGY ASSAY MARKET, FOR IMMUNOASSAY, BY REGION, 2018–2026 ($MILLION)
TABLE 06. IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY REGION, 2018–2026 ($MILLION)
TABLE 07. IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION)
TABLE 08. IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 10. IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 11. IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 12. IMMUNO-ONCOLOGY MARKET FOR MELANOMA, BY REGION, 2018–2026 ($MILLION)
TABLE 13. IMMUNO-ONCOLOGY MARKET FOR BLADDER CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 14. IMMUNO-ONCOLOGY MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15. IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 16. IMMUNO-ONCOLOGY ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2018–2026 ($MILLION)
TABLE 17. IMMUNO-ONCOLOGY ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2026 ($MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 21. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 22. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY PRODUCT, 2018–2026 ($MILLION)
TABLE 25. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 26. US IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 27. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY APPLICATION, 2018–2026 ($MILLION)
TABLE 28. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 29. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 30. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 31. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 32. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 33. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 34. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 35. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 38. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 39. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 40. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 42. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 43. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 44. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 46. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 47. FRANCE AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 48. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 50. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 51. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 54. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 55. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 56. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 57. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 58. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 59. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 60. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 63. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 64. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 66. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 67. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 68. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 69. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 70. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 71. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 72. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 73. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 74. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 75. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 76. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 77. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 80. REST OF ASIA PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 82. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 83. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 84. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 85. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 86. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 87. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 88. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 89. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 90. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 91. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 92. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 93. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 94. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 95. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 96. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 97. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 98. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 99. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 100. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 101. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 102. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 103. AGILENT: OPERATING SEGMENTS
TABLE 104. AGILENT: PRODUCT PORTFOLIO
TABLE 105. BIO-RAD: COMPANY SNAPSHOT
TABLE 106. BIO-RAD: OPERATING SEGMENTS
TABLE 107. BIO-RAD: PRODUCT PORTFOLIO
TABLE 108. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 109. CHARLES RIVER: OPERATING SEGMENTS
TABLE 110. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 111. ROCHE: COMPANY SNAPSHOT
TABLE 112. ROCHE: OPERATING SEGMENTS
TABLE 113. ROCHE: PRODUCT PORTFOLIO
TABLE 114. ILLUMINA: COMPANY SNAPSHOT
TABLE 115. ILLUMINA: OPERATING SEGMENTS
TABLE 116. ILLUMINA: PRODUCT PORTFOLIO
TABLE 117. NANOSTRING: COMPANY SNAPSHOT
TABLE 118. NANOSTRING: PRODUCT PORTFOLIO
TABLE 119. PERKINELMER: COMPANY SNAPSHOT
TABLE 120. PERKINELMER: OPERATING SEGMENTS
TABLE 121. PERKINELMER: PRODUCT PORTFOLIO
TABLE 122. QIAGEN: COMPANY SNAPSHOT
TABLE 123. QIAGEN: OPERATING SEGMENTS
TABLE 124. QIAGEN: PRODUCT PORTFOLIO
TABLE 125. SARTORIUS: COMPANY SNAPSHOT
TABLE 126. SARTORIUS: OPERATING SEGMENTS
TABLE 127. SARTORIUS: PRODUCT PORTFOLIO
TABLE 128. THERMO FISHER: COMPANY SNAPSHOT
TABLE 129. THERMO FISHER: OPERATING SEGMENTS
TABLE 130. THERMO FISHER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 06. MARKET SHARE ANALYSIS, 2018
FIGURE 07. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET: DRIVERS, RESTRAINT, AND OPPORTUNITY
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF IMMUNE-ONCOLOGY ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR IMMUNOASSAY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION), BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR MELANOMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR BLADDER CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR OTHERS , BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21. AGILENT: COMPANY SNAPSHOT
FIGURE 01. AGILENT: NET SALES, 2016–2018 ($MILLION)
FIGURE 02. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 03. AGILENT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 04. BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 05. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 06. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 07. CHARLES RIVER: NET SALES, 2016–2018 ($MILLION)
FIGURE 08. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 09. CHARLES RIVER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 10. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 11. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 12. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. ILLUMINA: NET SALES, 2016–2018 ($MILLION)
FIGURE 14. ILLUMINA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 15. REVENUE SHARE BY REGION, 2018 (%)
FIGURE 16. NANOSTRING: NET SALES, 2016–2018 ($MILLION)
FIGURE 17. NANOSTRING: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 20. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 21. QIAGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 22. QIAGEN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 23. QIAGEN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 24. SARTORIUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 25. SARTORIUS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26. SARTORIUS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27. THERMA FISHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. THERMO FISHER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 06. MARKET SHARE ANALYSIS, 2018
FIGURE 07. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET: DRIVERS, RESTRAINT, AND OPPORTUNITY
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF IMMUNE-ONCOLOGY ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR IMMUNOASSAY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION), BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR MELANOMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR BLADDER CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR OTHERS , BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21. AGILENT: COMPANY SNAPSHOT
FIGURE 01. AGILENT: NET SALES, 2016–2018 ($MILLION)
FIGURE 02. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 03. AGILENT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 04. BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 05. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 06. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 07. CHARLES RIVER: NET SALES, 2016–2018 ($MILLION)
FIGURE 08. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 09. CHARLES RIVER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 10. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 11. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 12. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. ILLUMINA: NET SALES, 2016–2018 ($MILLION)
FIGURE 14. ILLUMINA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 15. REVENUE SHARE BY REGION, 2018 (%)
FIGURE 16. NANOSTRING: NET SALES, 2016–2018 ($MILLION)
FIGURE 17. NANOSTRING: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 20. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 21. QIAGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 22. QIAGEN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 23. QIAGEN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 24. SARTORIUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 25. SARTORIUS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26. SARTORIUS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27. THERMA FISHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. THERMO FISHER: REVENUE SHARE BY REGION, 2018 (%)
